William Blair Reiterates Outperform Rating on Brickell Biotech (BBI) on SB Sale, "Valuation Holds Strong Risk/Reward Profile"
Tweet Send to a Friend
William Blair analyst Tim Lugo reiterated an Outperform rating on Brickell Biotech Inc. (NASDAQ: BBI) as the company announced the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
